Fig. 2: Effects of FBXO28 on HCC survival and proliferation in vitro and in vivo.
From: FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation
A FBXO28 mRNA levels in HCC and normal cohorts in TCGA. ***P < 0.001 (independent T-test). B, C Kaplan–Meier survival analysis of liver cancer patients. Correlation of FBXO28 expression and overall survival (OS) and relapse-free survival (RFS) were shown in (B) and (C), respectively. D, E Huh7 and HCCLM3 cells stably expressing FBXO28-Flag or a vector control (D) or Hep3b cells stably expressing shFBXO28 or shCtrl (E) were plated in 6-well plates for 14 days for colony formation assay. Representative images are shown. Data were presented as mean ± SD from three independent experiments. **P < 0.01 (independent T-test). F, G HCCLM3 cells stably expressing FBXO28-mGFP or mGFP control vector were inoculated into BALB/c nude mice. The length and width of the tumor masses were measured every 2 days as described in Materials and Methods. Average tumor weight on day 18th after inoculation (F) and tumor volume (G) during the indicated time were calculated (mean ± SD; n = 6 per group). Scale bar: 10 mm. *P < 0.05, **P < 0.01 versus the mGFP group at indicated time (independent T-test). NS no significance.
